Report says drooping revenues for branded drugs is the new normal

Share this article:

Amid a parade of reports that pharma isn't getting as much money for its new-to-market drugs as it once did, research by IBISWorld suggests that this the new normal.

The research firm expects industry branded sales to fall an average of 2.6% every year between 2013 and 2017 (branded drug sales are expected to finish 2012 down 3% to 5%). The firm blames generics for part of the downturn, but also says that the future of new drugs isn't going to balance things out any time soon. In fact, IBISWorld expects revenue to hit $115 billion in 2017, which amounts to a 0.4% annual gain between 2013 and 2017.

With this expected performance, the firm lands on solvency solutions that have become familiar: layoffs. In this case, IBISWorld expects the industry to lay off almost 1% of its workforce every year for the next five years, which translates into more than 125,000 lost jobs throughout the industry, including those in R&D.

The projected downsizing is not just in jobs. The research group expects the number of industry players to shrink through a combination of mergers and acquisitions and a dearth of new startups. Those companies that perform will be the ones with specialty pharmaceuticals flowing through their pipelines, a line the research firm expects will grow at twice the rate of traditional products between 2013 and 2017.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...